Patents by Inventor Rosalie Margaretha LUITEN

Rosalie Margaretha LUITEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monophenols and benzenediols sensitization of immune system against haptenized melanoma antigens
    Patent number: 9393219
    Abstract: The metabolization of certain phenols, monophenols or benzenediols into reactive quinone compounds, in particular ortho-quinones and related reactive intermediates, which is brought about by oxidation of monophenols and benzenediols by proteins exhibiting tyrosinase activity, such as human tyrosinase and the related proteins TRP1 and TRP2. The compounds function as haptens that become covalently bound to the tyrosinase enzymes, in particular to histidine moieties, in or near the catalytic site of proteins exhibiting tyrosinase activity, such as tyrosinase, TRP1 and TRP2. An immune response is then to be mounted against these haptenized auto-antigens to treat malignancies.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: July 19, 2016
    Assignees: ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM, ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
    Inventors: Wiete Westerhof, Cornelis Joseph Maria Melief, Rosalie Margaretha Luiten
  • SENSITIZATION OF IMMUNE SYSTEM AGAINST HAPTENIZED MELANOMA ANTIGENS
    Publication number: 20120315304
    Abstract: The metabolization of certain phenols, monophenols or benzenediols into reactive quinone compounds, in particular ortho-quinones and related reactive intermediates, which is brought about by oxidation of monophenols and benzenediols by proteins exhibiting tyrosinase activity, such as human tyrosinase and the related proteins TRP1 and TRP2. The compounds function as haptens that become covalently bound to the tyrosinase enzymes, in particular to histidine moieties, in or near the catalytic site of proteins exhibiting tyrosinase activity, such as tyrosinase, TRP1 and TRP2. An immune response is then to be mounted against these haptenized auto-antigens to treat malignancies.
    Type: Application
    Filed: June 11, 2012
    Publication date: December 13, 2012
    Applicants: ACADEMISCH ZIEKENHUIS LEIDEN, ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM
    Inventors: Wiete WESTERHOF, Cornelis Joseph Maria MELIEF, Rosalie Margaretha LUITEN